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To evaluate Interleukin 1-beta (IL-1β) serum and mononuclear leucocyte mRNA levels, also rs16944 
(−511C/T) genotype, in relation to hyperglycemic normalization in Type 2 diabetes (T2D) patients, 
we recruited 30 individuals recently T2D diagnosed with hyperglycemia studied at basal time and 
after 6 and 12 months of the normalization treatment. At basal time, the T polymorphic allele of 
the rs16944 was associated with lower IL-1β mRNA expression (p = 0.006); and higher glucose level 
was positive correlated to IL-1β protein levels (p = 0.015). After treatment, the individuals showed 
a significant decrease in glucose level (p = 0.003), but they did not express significant changes in 
the IL-1β serum levels. Surprisingly, we observed that the greater decreases in glucose level were 
associated to increased IL-1β serum levels (p = 0.040). This is the first follow-up study evaluating IL-1β 
mRNA expression and serum levels in hyperglycemic T2D individuals and after glycemic normalization 
treatment. The current results contribute to the knowledge of the relationship between inflammation 
and glucose metabolism in T2D.
Diabetes is a major public health concern which in recent decades has become a pandemic of uncontrollable 
proportions1. About 90% of the individuals with diabetes have type 2 diabetes (T2D). In Argentina the prevalence 
of T2D is close to 12%, similar to other Latin American countries and most of the industrialized countries2,3. 
Like many metabolic disorders, T2D is characterized by a systemic subclinical inflammation state, secondary 
to innate immunity hyperactivity4 related with an increase in the expression of pro-inflammatory cytokines. 
Interleukin 1-beta (IL-1β) is one of the most important pro-inflammatory molecules related to the systemic sub-
clinical inflammation in T2D5–9.
The deleterious effects of IL-1β on pancreatic β-cells are significantly increased in hyperglycemic states. It 
has been reported that increasing concentrations of glucose cause a rise in the production and release of IL-1β 
in pancreatic islets10. Both persistent and postprandial hyperglycemia have induced the expression of the IL-1β 
gene in rats, as evidenced by increased levels of IL-1β protein and mRNA in peripheral blood monocytes11,12. 
Furthermore, in a Japanese population study, circulating levels of IL-1β were found to positively correlate with 
fasting plasma glucose (FPG) levels, with a stronger correlation at FPG levels close to 125 mg/dL13. It was also 
reported that circulating levels of IL-1β were associated with the consumption of foods with high glycemic 
indexes in men and women with metabolic syndrome, a pre-diabetic state14.
T2D is one of the most complex, prevalent and heterogeneous diseases whose etiology is known to involve 
multiple interactions between genetic predisposing factors and environmental triggers15 but still remains to 
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be fully elucidated. Single nucleotide polymorphisms (SNPs) constitute the genetic basis of prevalent complex 
diseases and, in particular, functional SNPs described in the IL-1β gene have been associated with metabolic 
diseases16.
Given that the influence of micro environmental situations such as hyperglycemia on the expression levels of 
these pro-inflammatory molecules has not yet been explored in individuals with T2D, the principal aim of our 
work was to study IL-1β mRNA expression in mononuclear leucocytes and IL-1β levels in serum in T2D hyper-
glycemic individuals at three different time points, i.e. upon diagnosis, and after 6 and 12 months of treatment to 
achieve normoglycemia. We also evaluated the relationship between mRNA expression, serum levels of IL-1β, 
and the rs16944 SNP (-511C/T) genotype present in the promoter of the IL-1β gene.
Materials and Methods
Population. A prospective controlled study was conducted in individuals with T2D where the same indi-
vidual was analyzed pre and post-intervention with pharmacological treatment and changes in lifestyle. Over 
a period of two years, 30 individuals were randomly recruited with recently diagnosed T2D and hyperglycemia 
characterized by glycosylated hemoglobin (HbA1c) levels greater than 8% (64 mmol/mol). Out of these 30 indi-
viduals, 27 completed the prospective protocol and constituted the pre-intervention group (0 months of treat-
ment). Inclusion criteria were: unrelated adults over 18 years of age residing in urban areas of Buenos Aires. 
The exclusion criteria were: acute myocardial infarction, stroke, pregnancy, psychiatric disease, alcoholism, drug 
abuse, history or suspicion of pancreatitis, recent intake of hyperglycemic agents (<3 months), recent cancer and 
instability in body weight (loss > 3 kg in the last 6 months).
Each individual received personalized pharmacological treatment and underwent changes in diet and lifestyle 
to achieve the target metabolic control projected as HbA1c under 7% (53 mmol/mol). The pharmacological treat-
ment of choice in 19 individuals was metformin in doses between 500 and 2550 mg/day; 5 individuals received 
combined treatment with metformin and insulin; 1 individual received metformin and glibenclamide; 1 individ-
ual received vildagliptin; and 1 individual did not receive pharmacological treatment.
All procedures performed in studies involving human participants were in accordance with the ethical stand-
ards of the institutional research committee and with the 1964 Helsinki Declaration and its later amendments or 
comparable ethical standards. The study was approved by the Ethics Committees of the Hospital de Clínicas “José 
de San Martín” in Ciudad Autónoma de Buenos Aires, and all participants gave their written informed consent.
All individuals informed their age and gender. Anthropometric measurements (height, weight and waist cir-
cumference), and systolic and diastolic blood pressure (SBP and DBP, respectively) were determined by standard-
ized protocols. Body mass index (BMI) was calculated as weight (kg) / [height (m)]2. After 12 hours of overnight 
fasting, venous blood samples were drawn of every individual. Two aliquots of blood anticoagulated with EDTA 
K2 were reserved for mRNA and DNA extraction, and one aliquot of serum was reserved for measurement of 
IL-1β serum concentrations. All biochemical determinations were done immediately (<6 hours). FPG was deter-
mined using standardized procedures in plasma obtained by the centrifugation of blood anticoagulated with 
sodium fluoride. Triglycerides (TG), total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C) and 
low-density lipoprotein cholesterol (LDL-C) were determined in serum using standardized procedures. HbA1c 
was determined by an immunoturbidimetric method in an Architect system, with calibrators and controls that 
correlated with the national standardization program in the USA (NGSP and IFCC). The reference values for 
HbA1c were 4.40–6.40% (25–46 mmol/mol) for non-diabetic, and 6.00–8.00% (42–64 mmol/mol) for controlled 
diabetic individuals.
Quantification of serum IL-1β levels. IL-1β concentrations were measured in serum stored at −80 °C for 
short periods (<1 month) by chemiluminescence (Immulite – Siemens, DPC), according to the manufacturer’s 
instructions with a sensitivity of 1.5 pg/mL and a measurement range of 1.5-1000 pg/mL. The reference value for 
serum IL-1β was <5 pg/mL.
Relative quantification of IL-1β mRNA expression. The aliquot of blood reserved for mRNA extrac-
tion was processed immediately. Mononuclear cells were separated with Ficoll (FicollPaque Plus, GE Healthcare) 
and resuspended in guanidinium thioisocyanate (TRIzol, Invitrogen Corp., Carlsbad, CA) for subsequent 
extraction of total RNA. Under these conditions, samples were stored at −80 °C for a maximum period of 3 
months. The quality of the extracted RNA was checked on 1% agarose gels. The possible remaining DNA was 
removed with DNAseI (Amplification Grade DNAseI, Life Technologies). RNA was reverse-transcribed with 
Moloney Murine Leukemia Virus Reverse Transcriptase (M-MLV RT, Invitrogen Corp., Carlsbad, CA) and 
DNA hexamers as random primers (Life Technologies) to obtain the first strand of the complementary DNA 
(cDNA). Gene expression was analyzed by quantitative real time PCR with the StepOne system (Applied 
Biosystems), using the following primers: IL-1β: forward 5′-ATGATGGCTTATTACAGTGGCAA-3′ and reverse 
5′-GTCGGAGATTCGTAGCTGGA-3′; and GADPH: forward 5′-TGCACCACCAACTGCTTAGC-3′ and 
reverse 5′-GGCATGGACTGTGGTCATGAG-3′ (Applied Biosystems). PCRs were performed in a final volume 
of 20 µL containing 20 ng RNA, 1X SYBR Green Master Mix (SYBR Select, Applied Biosystems) and 250 nM 
of each primer. The PCR conditions were: 2 min at 50 °C and 10 min at 95 °C, followed by 40 cycles of 15 sec 
at 95 °C and 1 min at 60 °C and a melting curve was performed in every assay to evaluate the specificity of the 
primers with 1 cycle of 15 sec at 95 °C, 1 min at 60 °C, and 1 min at 95 °C with a temperature ramp of 0.1 °C/
sec. Each sample was analyzed in duplicate, with GADPH as normalizing control gene. The pre-intervention 
and both post-intervention samples for each individual were amplified in the same assay, and all measurements 
included the determination of a no-template negative control in which the cDNA was substituted by water. The 
2−ΔΔCt method was employed for relative quantification of gene expression17. ΔCt was calculated as the difference 
between the Ct of the target gene (IL-1β) minus the Ct of the endogenous control gene (GADPH) for each sample. 
3Scientific RepoRtS |         (2020) 10:9985  | https://doi.org/10.1038/s41598-020-66751-x
www.nature.com/scientificreportswww.nature.com/scientificreports/
For the pre-intervention group analysis, ΔΔCt was calculated as the ΔCt of each pre-intervention sample minus 
the average ΔCt of all pre-intervention samples, and the 2−ΔΔCt calculated represented the fold change in mRNA 
expression of each pre-intervention sample in comparison with the average expression. For the prospective anal-
ysis, ΔΔCt was calculated as the ΔCt of the post-intervention sample (6 and 12 months) minus the ΔCt of the 
pre-intervention sample (0 months), and the 2−ΔΔCt calculated represented the fold change in mRNA expression 
after treatment. We also calculated the 2−ΔCt of each sample to evaluate the IL-1β mRNA expression levels nor-
malized by the endogenous control at each time of the study.
Genotyping of rs16944. We genotyped the rs16944 (-511C/T), located in the promoter region of the IL-1β 
gene. The aliquot of blood reserved for DNA extraction was conserved at -4 °C for short periods of time (<3 
months) until its use. DNA was extracted by the cetyltrimethylammonium (CTAB) method18 quantified with a 
Qubit 2.0 Fluorometer (Invitrogen Corp., Carlsbad, CA, USA). DNA samples were prepared at concentrations of 
3.3 ng/μL and genotyped by KASP (Kompetitive Allele Specific PCR) performed by LGC Genomics (http://www.
lgcgroup.com). KASP technology is a uniplex SNP genotyping platform developed by LGC Genomics which 
utilizes a competitive allele-specific PCR. The KASP assay was carried out with primers with a universal fluores-
cent resonance energy transfer (FRET) cassette (FAM and HEX), ROX passive reference dye, Taq polymerase, 
free nucleotides and MgCl2 in an optimized buffer solution. The primer sequences were specific to the SNP to be 
targeted and were designed by LGC Genomics. They consisted in two competitive allele-specific forward primers 
and one common reverse primer. Each forward primer incorporates an additional tail sequence that corresponds 
with one of two universal FRET cassettes.
Statistical evaluation. Statistical analyses were performed using SPSS version 20.0 (IBM Corp., Armonk, 
NY, USA). A p value below 0.05 was considered statistically significant. We considered the logarithms of the 2−
ΔΔCt values for the analysis of mRNA expression and the logarithms of the pg/mL for the analysis of serum IL-1β 
levels. In the pre-intervention group, we used a multiple linear regression with age, gender and weight as covar-
iates to assess the association between IL-1β mRNA expression, serum IL-1β levels and biochemical and clinical 
variables. To evaluate the effect of hyperglycemia on IL-1β expression, we created groups with different levels of 
HbA1c (<10% (<86 mmol/mol); 10-11.99% (86- 107- mmol/mol); ≥12% (108 mmol/mol)) and FPG ( < 140 mg/
dL; 140-199 mg/dL; ≥200 mg/dL) and compared IL-1β mRNA expression and serum IL-1β concentrations in 
each level by multiple linear regression, with age, gender and weight as covariates.
The Hardy-Weinberg equilibrium was assessed by Chi square test. The association between the rs16944 SNP 
genotype (through dominant, recessive and allelic load models) and IL-1β mRNA expression was also analyzed by 
multiple linear regression, with age, gender and weight as covariates. The biochemical and clinical variables and 
the levels of gene expression in the individuals in each stage of the study were compared by Friedman test. IL-1β 
mRNA expression was analyzed by comparing the logarithms of the 2−ΔCt values of the pre and post-intervention 
stages. The variations in serum IL-1β levels and biochemical and clinical variables were calculated as the value of 
the post-intervention sample (6 and 12 months) minus the value of the pre-intervention sample (0 months). The 
fold change in IL-1β mRNA expression and variations in serum protein levels were compared with the variations 
in biochemical and clinical variables, with the rs16944 SNP genotype, with the type of treatment and with the 
dose of each antidiabetic drug, by multiple linear regression with age, gender and BMI as covariates.
Ethical approval. All procedures performed in studies involving human participants were in accordance 
with the ethical standards of the institutional research committee (Ophthalmology Clinic, Department of 
Medicine and Science of Ageing) and with the 1964 Helsinki Declaration and its later amendments or compara-
ble ethical standards.
Informed consent. Informed consent was obtained from all individual participants included in the study.
Results
Pre-intervention group analysis. The overall population consisted of 7 women (23.33%) and 23 men 
(76.67%), with a mean age of 48.17 years (SD = 12.37; range: 23–69 years). Table 1 shows the biochemical and 
clinical profile of the pre-intervention group, which was the expected one for individuals with T2D.
The median IL-1β serum concentration at the beginning of the study was 10.40 pg/mL (interquartile range 
[IQR]: 1.50–16.35 pg/mL). Thirteen individuals (43.33%) showed values within the reference range (<5 pg/mL) 
and 17 individuals (56.67%) showed values above it (≥5 pg/mL). At basal time, serum IL-1β levels were positively 
correlated with FPG (Fig. 1). IL-1β mRNA expression did not correlate with any biochemical-chemical variable 
analyzed.
The genotypic frequencies of rs16944 in the IL-1β gene were as follows: 8 individuals were CC (26.7%), 15 
individuals CT (50.0%) and 7 individuals TT (23.3%). The SNP was in good accordance with the expected gen-
otype distributions calculated by the Hardy–Weinberg law (p = 0.995). The study through a dominant model 
showed a significant association between the presence of the T polymorphic allele (genotypes CT and TT) and 
lower IL-1β mRNA expression (Fig. 2).
Post-intervention group analysis. The prospective study was carried out in the 27 individuals who fin-
ished the protocol. This population consisted of 7 women (25.90%) and 20 men (74.10%), with a mean age of 49.48 
years (SD = 12.33; range: 23-69 years). Table 1 shows the biochemical and clinical profile of the post-intervention 
group. The individuals reached the target of glycemic control after 6 months of treatment and maintained it after 
12 months, as demonstrated by the significant decrease in FPG and HbA1c at post-intervention stages. When 
other biochemical-clinical characteristics were analyzed, a significant decrease was observed in weight and BMI 
4Scientific RepoRtS |         (2020) 10:9985  | https://doi.org/10.1038/s41598-020-66751-x
www.nature.com/scientificreportswww.nature.com/scientificreports/
after 6 months of treatment, followed by a significant increase in HDL-C after 12 months of treatment. There were 
no significant changes in any of the other metabolic variables.
Of note, even if IL-1β mRNA expression and serum protein levels presented no significant differences with 
respect to pre-intervention time (Fig. 3), the sharper decreases in FPG and HbA1c after treatment were associated 
with greater reductions in IL-1β protein levels (Fig. 4).
Discussion
The inflammatory response could be a critical pathophysiological component in the development of T2D19. 
Among inflammatory cytokines, IL-1β is considered the key pro-inflammatory factor in T2D-associated inflam-
mation, as high glucose levels induce metabolic stress and an inflammatory response involving cytokine secre-
tion, islet immune-cell infiltration and β-cell apoptosis20, particularly by overproduction of IL-1β21.
Several preclinical and clinical studies have shown the usefulness of IL-1 antagonist therapy9,19,22,23. For 
instance, trials have shown that blocking IL-1 signaling by recombinant IL-1 receptor antagonist Anakinra22 or 
neutralizing IL-1β through monoclonal antibodies Canakinumab24, Gevokizumab25 and LY218910226 result in an 
improvement in glycemic control in T2D patients27. However, it was recently reported that Canakinumab failed 
to prevent progression from prediabetes to T2D28.
In the present work we assessed mRNA expression and serum protein levels of IL-1β in newly diagnosed T2D 
individuals with hyperglycemia and after 6 and 12 months of treatment, when they achieved their glycemic target 
control. Also, we evaluated the association between the rs16944 genotype with mRNA expression, serum levels of 
IL-1β, biochemical and clinical variables.
IL-1β is produced mainly by monocytes (MO), and hyperglycemia may regulate its production through 
the assembly of a nucleotide-binding domain and leucine-rich repeat containing family pyrin (NLRP3) of the 
inflammasome, a cytosolic multi-protein platform where the inactive pro-IL-1β is cleaved into an active form 
via caspase-1 activity29,30. Recently, Kousathana et al.31 provide evidence for a qualitative impairment of cytokine 
production and innate immune response in T2D individuals. They observed defective production of IL-1β by cir-
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Table 1. Biochemical and clinical characteristics of the population at each time of the study. BMI: body mass 
index; SBP: systolic blood pressure; DBP: diastolic blood pressure; HbA1c: glycated hemoglobin; FPG: fasting 
plasma glucose; TC: total cholesterol; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density 
lipoprotein cholesterol; TG: triglycerides; m: median; IQR: interquartile range; NS: not significant. Statistical 
evaluation: Friedman test.
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were restored by a proper glycemic control. The referred study highlighted the importance of glucose manage-
ment in the maintenance of appropriate immune function in patients with T2D31. In addition, Misaki et al. stud-
ied healthy and preclinical middle-aged non-overweight and overweight Japanese men, and found that plasma 
IL-1β concentrations were significantly associated with glucose levels up to 125 mg/dL13. Worth highlighting, 
the current study has replicated those results in a T2D glycemic normalization follow-up study for the first time. 
Figure 1. IL-1β mRNA expression (A,B) and serum protein levels (C,D) at the basal time of the study (pre-
intervention group), according to HbA1c and fasting plasma glucose levels. For each data set the median and 
interquartile range are informed. Statistical evaluation: Multiple linear regression. Covariates: age, gender and 
weight. HbA1c: glycated hemoglobin; FPG: fasting plasma glucose; r: regression coefficient; NS: not significant.
Figure 2. IL-1β mRNA expression at the basal time of the study (pre-intervention group), according to rs16944 
genotype. For each data set the median and interquartile range are informed. Statistical evaluation: Multiple 
linear regression. Covariates: age, gender and weight. r: regression coefficient.
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We studied a cohort of hyperglycemic states (≥126 mg/dL) and observed that individuals with higher FPG levels 
presented higher levels of serum IL-1β in the pre-intervention group, in agreement with the above-mentioned 
findings by Kousathana et al.31. Also, Ruscitti et al. observed a significant increase in NLRP3 expression and IL-1β 
production by MO of patients affected by T2D after 24 h of incubation with different concentrations of glucose32. 
In other words, serum pro-inflammatory cytokines, including IL-1β, were significantly higher in individuals with 
hyperglycemia compared with controls, associated to significantly increased oxidative stress33.
It should be considered that IL-1β expression regulation is highly complex and depends on at least two inde-
pendent mechanisms, one at the level of transcriptional activation and another one at the level of translational 
efficiency34, which could justify the dissociation between mRNA and protein levels reported here. In contrast, the 
association between glucose levels and serum protein levels of IL-1β suggests that glucose levels are one of the 
factors exerting an effect on the expression of IL-1β at the level of the translation.
In addition, we found that after treatment, a significant decrease was observed in FPG and HbA1c, with no 
significant changes in IL-1β serum levels. However, an association was found between the greater decreases in 
FPG and HbA1c and the greater –though non-significant– increases in the circulating levels of IL-1β observed 
after treatment. The same finding was reported by Kousathana et al., who provide evidence for the restored pro-
duction of IL-1β by circulating monocytes after proper glycemic control probably due to activation of the NLRP3 
inflammasome31. As an alternative explanation for our findings, endoplasmic reticulum (ER) dysfunction in pan-
creatic β cells is one of the pathogenic mechanisms which determine the development of T2D and is prompted by 
hyperglycemia, among other mechanisms35,36. Considering that hyperglycemia may have the same effects on ER 
and circulating monocytes, the decrease in glucotoxicity may favor the production of proteins such as IL-1β. This 
could justify the negative association between the variations in IL-1β serum levels and the variations in FPG and 
HbA1c after treatment, not related to changes in IL-1β mRNA expression.
Our current results also show that the rs16944 genotype (-511C/T) in the promoter of the IL-1β gene may 
have an effect on gene transcription, where the presence of the polymorphic T allele was associated with a lower 
Figure 3. IL-1β mRNA expression and serum levels at each time of the study and variation after 6 and 12 
months of treatment. (A) Levels of IL-1β mRNA expression and (B) fold change after treatment. (C) Levels 
of IL-1β serum protein and (D) ratio of variation after treatment calculated as the serum protein level after 
treatment (at 6 and 12 months) divided by the initial serum protein level (0 months). For each data set the 
median and interquartile range are informed. Statistical evaluation: Friedman test. All comparisons were not 
significant.
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expression of mRNA. This is in agreement with previous publications were a specific IL-1β haplotype (-3893G, 
-1464G, -511C and -31T) in the promoter region of IL-1β was associated with increased IL-1β mRNA37. Moreover, 
significantly lower secretion of IL-1β was found to be associated with CTC haplotype -1470G/C, -511T/C, and 
-31C/T in the promoter of the gene38. Polymorphisms in the IL-1β gene promoter region alter lipopolysaccharide 
(LPS) effects on IL-1β gene transcription, leading to susceptibility to inflammatory diseases39. Wen et al. have 
suggested that IL-1β promoter haplotypes influence the expression and transcriptional activity of the IL-1β gene 
after LPS exposure and observed gene upregulation in subjects with haplotype GCT (-1470G, -511C, and -31T)40.
It must be taken into consideration that this study was carried out in a population with different proportions 
of men and women and further and longer studies should be undertaken to determine the effect of ER stress on 
IL-1β production. Also, longer after-treatment studies may prove interesting to determine the effect of hypergly-
cemia normalization on the expression of IL-1β.
To resume, this report shows IL-1β mRNA expression level association with the genotype of the rs16944 SNP 
present in the promoter of the IL-1β gene, a positive association between IL-1β protein levels and FPG and a neg-
ative association between variations in IL-1β protein levels and variations in FPG and HbA1c.
conclusions
To our knowledge, this is the first follow-up study evaluating IL-1β mRNA expression and serum levels in hyper-
glycemic T2D individuals and after glycemic normalization treatment. Even if longer after-treatment studies may 
prove interesting to determine the effect of hyperglycemia normalization on the expression of IL-1β, the current 
results contribute to the knowledge of the relationship between inflammation and changes in glucose metabolism 
in T2D. Individuals with T2D constitute a heterogeneous group, for which treatment objectives must be individ-
ualized. In this context, it is crucial to find new molecular targets for the development of new drugs, guiding the 
therapeutic strategy in a personalized way (pharmacogenetics).
Disclosure
The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of 
the research reported.
The study was not pre-registered in a national or international database.
Figure 4. Variations in IL-1β serum levels in function of the variations in HbA1c (A,B) and fasting plasma 
glucose (C,D) levels after 6 and 12 months of treatment. Statistical evaluation: Multiple linear regression. For 
graphic purposes, the variations in IL-1β serum levels are shown as the differences of the logarithms. Covariates: 
age, gender and weight. HbA1c: glycated hemoglobin; FPG: fasting plasma glucose; r: regression coefficient; NS: 
not significant.
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Data availability
The data that support the findings of this study are available from the corresponding author upon request. Not 
public available due to privacy patient restriction.
Received: 10 February 2020; Accepted: 19 May 2020;
Published: xx xx xxxx
References
 1. Zimmet, P., Alberti, K. G. & Shaw, J. Global and societal implications of the diabetic epidemic. Nature 414, 782–7 (2001).
 2. Schargrodsky, H. et al. CARMELA: assessment of cardiovascular risk in seven Latin American. Am J Med 121, 58–65 (2008).
 3. De Sereday, M. S. et al. Prevalence of diabetes, obesity, hypertension and hyperlipidemia in the central area of Argentina. Diabetes 
Metab 30, 335–9 (2004).
 4. Gallagher, E. J., LeRoith, D. & Karnieli, E. The metabolic syndrome-from insulin resistance to obesity and diabetes. Endocrinol 
Metab Clin North Am 37(3), 559–79 (2008).
 5. Banerjee, M. & Saxena, M. Interleukin-1 (IL-1) family of cytokines: role in type 2 diabetes. Clin Chim Acta 413, 1163–70. (2012).
 6. Sepehri, Z. et al. Inflammasomes and type 2 diabetes: An updated systematic review. Immunol Lett 192, 97–103 (2017).
 7. Dinarello, C. A. Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol 27, 519–50. (2009).
 8. Maedler, K. et al. Low concentration of interleukin-1 ß induces FLICE-inhibitory protein-mediated beta cell proliferation in human 
pancreatic islets. Diabetes 55, 2713–22 (2006).
 9. Donath, M. Y. et al. Islet inflammation in type 2 diabetes: from metabolic stress to therapy. Diabetes Care 31, 161–4 (2008).
 10. Maedler, K. et al. Glucose induced ß cell production of IL-1 ß contributes to glucotoxicity in human pancreatic islets. J Clin Invest 
110, 851–60 (2002).
 11. Fukaya, N., Mochizuki, K., Shimada, M. & Goda, T. The α-glucosidase inhibitor miglitol decreases glucose fluctuations and gene 
expression of inflammatory cytokines induced by hyperglycemia in peripheral leukocytes. Nutrition 25, 657–67 (2009).
 12. Dasu, M. R., Devaraj, S. & Jialal, I. High glucose induces IL-1β expression in human monocytes: mechanistic insights. Am J Physiol 
Endocrinol Metab 293, 337–46 (2007).
 13. Misaki, Y. et al. Plasma interleukin-1β concentrations are closely associated with fasting blood glucose levels in healthy and 
preclinical middle-aged nonoverweight and overweight Japanese men. Metabolism 59, 1465–71. (2010).
 14. Kallio, P. et al. Inflammation markers are modulated by responses to diets differing in postprandial insulin responses in individuals 
with the metabolic syndrome. Am J Clin Nutr 87, 1497–1503 (2008).
 15. Doria, A., Patti, M. E. & Kahn, C. R. The emerging genetic architecture of type 2 diabetes. Cell Metab 8, 186–200 (2008).
 16. Vangsted, A. J. et al. A functional polymorphism in the promoter region of the IL1B gene is associated with risk of multiple myeloma. 
Br J Haematol 158, 515–8 (2012).
 17. Livak, K. J. & Schmittgen, T. D. Analysis of relative gene expression data using real-time quantitative PCR and the 2−ΔΔCt method. 
Methods 25, 402–8 (2001).
 18. Gustincich, S., Manfiolett, G., Del Sal, G., Schneider, C. & Carninci, P. A fast method for high-quality genomic DNA extraction from 
whole human blood. Bio Techniques 11, 298–302 (1991).
 19. Donath, M. Y. & Shoelson, S. E. Type 2 diabetes as an inflammatory disease. Nat Rev Immunol 11, 98–107 (2011).
 20. Masters, S. L. et al. Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-
1beta in type 2 diabetes. Nat Immunol 2010(11), 897–904 (2010).
 21. Maedler, K. et al. Glucose-induced beta cell production of IL-1beta contributes to glucotoxicity in human pancreatic islets. The. 
Journal of clinical investigation 110, 851–60 (2002).
 22. Larsen, C. M. et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med 356, 1517–26 (2007).
 23. Ruscitti, P. et al. Efficacy of inhibition of IL-1 in patients with rheumatoid arthritis and type 2 diabetes mellitus: two case reports and 
review of the literature. J Med Case Rep 2, 123 (2015).
 24. Dhimolea E Canakinumab mAbs 2:3-13 (2010).
 25. Cavelti-Weder, C. et al. Effects of gevokizumab on glycemia and inflammatory markers in type 2 diabetes. Diabetes care 35, 1654–62. 
(2012).
 26. Sloan-Lancaster, J. et al. Double-blind, randomized study evaluating the glycemic and anti-inflammatory effects of subcutaneous 
LY2189102, a neutralizing IL-1beta antibody, in patients with type 2 diabetes. Diabetes care 36, 2239–46 (2013).
 27. Cavelti-Weder, C. et al. Development of an Interleukin-1β Vaccine in Patients with Type 2 Diabetes. Mol Ther 24, 1003–12 (2016).
 28. Everett, B. M. et al. Anti-Inflammatory Therapy With Canakinumab for the Prevention and Management of Diabetes. J Am Coll 
Cardiol 21, 2392–2401 (2018).
 29. Schroder, K., Zhou, R. & Tschopp, J. The NLRP3 inflammasome: a sensor for metabolic danger? Science 327, 296–300 (2010).
 30. Menu, P. & Vince, J. E. The NLRP3 inflammasome in health and disease: the good, the bad and the ugly. Clin Exp Immunol 166, 1–15 
(2011).
 31. Kousathana, F. et al. Defective production of interleukin-1 beta in patients with type 2 diabetes mellitus: Restoration by proper 
glycemic control. Cytokine 90, 177–184 (2017).
 32. Ruscitti, P. et al. Monocytes from patients with rheumatoid arthritis and type 2 diabetes mellitus display an increased production of 
interleukin (IL)-1β via the nucleotide-binding domain and leucine-rich repeat containing family pyrin 3(NLRP3)-inflammasome 
activation: a possible implication for therapeutic decision in these patients. Clin Exp Immunol 182, 35–44 (2015).
 33. Li, J., Huang, M. & Shen, X. The association of oxidative stress and pro-inflammatory cytokines in diabetic patients with 
hyperglycemic crisis. J Diabetes Complications 28, 662–6 (2014).
 34. Schindler, R., Clark, B. D. & Dinarello, C. A. Dissociation between interleukin-1 beta mRNA and protein synthesis in human 
peripheral blood mononuclear cells. J Biol Chem 265, 10232–7 (1990).
 35. Eizirik, D. L., Cardozo, A. K. & Cnop, M. The Role for Endoplasmic Reticulum Stress in Diabetes Mellitus. Endocrine Reviews 29, 
42–61 (2008).
 36. Hotamisligil, G. S. Endoplasmic Reticulum Stress and the Inflammatory Basis of Metabolic Disease. Cell 140, 900–17 (2010).
 37. Landvik, N. E. et al. A specific interleukin-1beta haplotype correlates with high levels of IL1B mRNA in the lung and increased risk 
of non-small cell lung cancer. Carcinogenesis 30, 1186–92 (2009).
 38. Wen, A. Q. et al. Clinical relevance of IL-1beta promoter polymorphisms (−1470, −511, and −31) in patients with major trauma. 
Shock 33, 576–82. (2010).
 39. Hall, S. K. et al. Correlation of polymorphic variation in the promoter region of the interleukin-1 beta gene with secretion of 
interleukin-1 beta protein. Arthritis Rheum 50, 1976–83. (2004).
 40. Wen, A. Q. et al. Effects of haplotypes in the interleukin 1beta promoter on lipopolysaccharide-induced interleukin 1beta expression. 
Shock 26, 25–30 (2006).
9Scientific RepoRtS |         (2020) 10:9985  | https://doi.org/10.1038/s41598-020-66751-x
www.nature.com/scientificreportswww.nature.com/scientificreports/
Acknowledgements
We are very grateful to the volunteers who consented to participate in this study. The authors thank Silvia 
Mereles and Francisca Esquivel from Unión Obrera Metalúrgica (UOM) for their collaboration. This work was 
financially supported by the unrestricted grant PICTO Glaxo 0070 of Agencia Nacional de Promoción Científica 
y Tecnológica (ANPCyT) and Glaxo Smith Kline Argentina S.A. (GSK), to Gustavo Daniel Frechtel; by the 
unrestricted grant of Universidad de Buenos Aires IC 20720120100003, Scientific Program 2013-2016, to Gloria 
Edith Cerrone, unrestricted grant of Fundación Barceló, Scientific Program 2018, to Gloria Edith Cerrone.
Author contributions
Conceptualization: F.G.D. & C.G.E. Conceived and designed the experiments: F.G.D. & C.G.E. Provided the 
patients samples and the clinical data for the study: L.M.A. Performed the experiments: I.M.A.E., B.M.F., S.M., 
L.M.A., C.G.E. Formal Analysis: I.M.A.E., B.M.F., S.M., L.M.A., F.G.D., C.G.E. Analyzed the data: I.M.A.E., 
B.M.F., S.M., F.G.D. & C.G.E. Funding Acquisition: F.G.D. & C.G.E. Writing – Review & Editing: I.M.A.E., B.M.F., 
S.M., F.G.D. & C.G.E.
Competing interests
The authors declare no competing interests.
Additional information
Supplementary information is available for this paper at https://doi.org/10.1038/s41598-020-66751-x.
Correspondence and requests for materials should be addressed to G.E.C.
Reprints and permissions information is available at www.nature.com/reprints.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Cre-
ative Commons license, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons license and your intended use is not per-
mitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the 
copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
 
© The Author(s) 2020
